Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergoogle.com
Google Alert - HER2-ADC
Get the latest updates from Google Alert - HER2-ADC directly as they happen.
Follow now 126 followers
Latest posts
Last updated about 3 hours ago
Alphamab Oncology's 2025 Interim Results and Strategic Pipeline Progress - AInvest
about 3 hours ago
- Alphamab Oncology advances two key candidates in 2025: HER2-targeted ADC JSKN003...
Alphamab Oncology Reports 2025 Interim Results and Business Highlights
about 4 hours ago
Release HER2-negative BC related clinical data. JSKN033. JSKN033 is a proprietary high-concentration...
Treatment With ADCs Advances in Endocrine-Refractory Breast Cancer
about 8 hours ago
During a live event, Kit Yu Lu, MD, discussed data on antibody-drug...
Anne Schuckman on Perioperative Treatment for Muscle-Invasive Bladder Cancer
about 11 hours ago
In addition, there has been increasing interest in investigating the role of...
HER2-Negative Metastatic Breast Cancer Market Massive Growth opportunity Ahead
about 14 hours ago
The last decade has seen major progress: CDK4/6 inhibitors, PARP inhibitors, immunotherapy...
HER2-Negative Breast Cancer Market Detailed Industry Report Analysis 2025-2034
about 14 hours ago
CDK4/6 inhibitors, PARP inhibitors, immunotherapy agents, and antibody-drug conjugates (ADCs) are now...
Progression-Free Survival vs Overall Survival: Rethinking Endpoints in NSCLC
about 15 hours ago
There is also a HER2 ADC that requires HER2 IHC testing. If...
Merck Initiates HERTHENA-Breast04 Trial of Patritumab Deruxtecan in Metastatic Breast ...
1 day ago
... HER2 directed ADC. The primary endpoints are progression-free survival and overall...
Merck Initiates Phase 3 Trial for Metastatic Breast Cancer Treatment - AInvest
1 day ago
... HER2-directed ADC (trastuzumab deruxtecan). The primary endpoints of the trial are...
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with ... - Merck.com
2 days ago
... HER2 directed ADC (trastuzumab deruxtecan). Randomization will be stratified by HER2...
Trastuzumab Deruxtecan Approved in Japan for HER2-Low or -Ultralow Metastatic Breast Cancer
2 days ago
In with HER2-low subgroup, the antibody-drug conjugate (n = 359; ADC) led...
Antibody Drug Conjugate Competitive Landscape & Pipeline 2025 - The Globe and Mail
2 days ago
Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC...